Global and Regional Aspirin Market

Aspirin Comprehensive Study by Type (99.5% Purity, 99% Purity, Others), Application (Tablets Product, Capsule Product, Others), End-User (Hospitals, Ambulatory Surgical Center (ASC), Others) Players and Region - Global Market Outlook to 2028

Aspirin Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Aspirin?
Aspirin is a novel technology that aims to reduce pain in conditions including migraines, cluster headache and other head and facial pain. Moreover, Aspirin is the most popular brand available for a headache across the world. In 2016, according to the World Health Organization (WHO), a prevalence of a headache among adults is about 50%. On the other hand, it is estimated that nearly 700 to 1000 clinical trials are conducted every year for aspirin to find its additional usage.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBayer (Germany), Novacap (Canada), Shiono Chemical Co. (Japan), Chemische Fabrik Weyl Gmbh (Germany), Eli Lilly And Co (United States), Industria Quimica Andina Y Cia Sa (Colombia), Jqc Huayin Pharmaceutical Co Ltd (China), Lohmann Lts (Germany), Novacyl Sas (France), Upjohn Co (United States), Shandong Xinhua Pharmaceutical Co Ltd (China), The Andhra Sugars Ltd (India), Dow Chemical Co (United States), Alfred Benzon As (Denmark), Eurand America Inc (United States), Industries Monfel S.A. De C.V. (Mexico), Nanjing Pharmaceutical Factory (China) and Jilin Pharmaceutical (United States)


The study covers a detailed analysis segmented by key business segments i.e. by type (99.5% Purity, 99% Purity and Others) , by application (Tablets Product, Capsule Product and Others) and major geographies. Research Analyst at AMA predicts that Chinese, United States Players will contribute to the maximum growth of Global Aspirin market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Aspirin market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Bayer (Germany), Novacap (Canada), Shiono Chemical Co. (Japan), Chemische Fabrik Weyl Gmbh (Germany), Eli Lilly And Co (United States), Industria Quimica Andina Y Cia Sa (Colombia), Jqc Huayin Pharmaceutical Co Ltd (China), Lohmann Lts (Germany), Novacyl Sas (France), Upjohn Co (United States), Shandong Xinhua Pharmaceutical Co Ltd (China), The Andhra Sugars Ltd (India), Dow Chemical Co (United States), Alfred Benzon As (Denmark), Eurand America Inc (United States), Industries Monfel S.A. De C.V. (Mexico), Nanjing Pharmaceutical Factory (China) and Jilin Pharmaceutical (United States).

Market Overview:
In January 2021, Eli Lilly and Company acquired Prevail Therapeutics Inc. This acquisition establishes a new modality for drug discovery and development at Lilly and expands Lilly's research efforts through the creation of gene therapy programs that will build on Prevail's portfolio of clinical-stage and pre-clinical neuroscience assets.

Of late, Autonomic Technologies Inc (ATI) is investing in the development of electronic aspirin. The company is mainly focusing on the development of new therapies for the treatment of cluster headaches. For instance, in March 2017, ATI received an expanded indication (CE mark) in Europe for the Pulsante SPG Microstimulator system to include pain relief for highly affected migraine patients.

Influencing Trend:
Surging use of electronic aspirin

Market Growth Drivers:
Increasing headache, stress-related work and rise in demand for advanced medical device and The surging number of cigarette consumers

Challenges:
Lack of awareness among people in underdeveloped nations

Restraints:
Stringent regulation for medical devices and lack of clinical data

Opportunities:
An increasing future expectation for electronic aspirin

Key highlights of the Global Aspirin market Study:
• CAGR of the market during the forecast period 2022-2028
• In-depth information on growth factors that will accelerate the Aspirin market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Aspirin market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Aspirin Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Aspirin market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Aspirin market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters. and Association and government bodies.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • 99.5% Purity
  • 99% Purity
  • Others
By Application
  • Tablets Product
  • Capsule Product
  • Others
By End-User
  • Hospitals
  • Ambulatory Surgical Center (ASC)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing headache, stress-related work and rise in demand for advanced medical device
      • 3.2.2. The surging number of cigarette consumers
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness among people in underdeveloped nations
    • 3.4. Market Trends
      • 3.4.1. Surging use of electronic aspirin
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Aspirin, by Type, Application, End-User and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Aspirin (Value)
      • 5.2.1. Global Aspirin by: Type (Value)
        • 5.2.1.1. 99.5% Purity
        • 5.2.1.2. 99% Purity
        • 5.2.1.3. Others
      • 5.2.2. Global Aspirin by: Application (Value)
        • 5.2.2.1. Tablets Product
        • 5.2.2.2. Capsule Product
        • 5.2.2.3. Others
      • 5.2.3. Global Aspirin by: End-User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Center (ASC)
        • 5.2.3.3. Others
      • 5.2.4. Global Aspirin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Aspirin (Price)
      • 5.3.1. Global Aspirin by: Type (Price)
  • 6. Aspirin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novacap (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Shiono Chemical Co. (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Chemische Fabrik Weyl Gmbh (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly And Co (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Industria Quimica Andina Y Cia Sa (Colombia)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Jqc Huayin Pharmaceutical Co Ltd (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lohmann Lts (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novacyl Sas (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Upjohn Co (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Shandong Xinhua Pharmaceutical Co Ltd (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. The Andhra Sugars Ltd (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Dow Chemical Co (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Alfred Benzon As (Denmark)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Eurand America Inc (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Industries Monfel S.A. De C.V. (Mexico)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Nanjing Pharmaceutical Factory (China)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Jilin Pharmaceutical (United States)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
  • 7. Global Aspirin Sale, by Type, Application, End-User and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Aspirin (Value)
      • 7.2.1. Global Aspirin by: Type (Value)
        • 7.2.1.1. 99.5% Purity
        • 7.2.1.2. 99% Purity
        • 7.2.1.3. Others
      • 7.2.2. Global Aspirin by: Application (Value)
        • 7.2.2.1. Tablets Product
        • 7.2.2.2. Capsule Product
        • 7.2.2.3. Others
      • 7.2.3. Global Aspirin by: End-User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Center (ASC)
        • 7.2.3.3. Others
      • 7.2.4. Global Aspirin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Aspirin (Price)
      • 7.3.1. Global Aspirin by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Aspirin: by Type(USD Million)
  • Table 2. Aspirin 99.5% Purity , by Region USD Million (2017-2022)
  • Table 3. Aspirin 99% Purity , by Region USD Million (2017-2022)
  • Table 4. Aspirin Others , by Region USD Million (2017-2022)
  • Table 5. Aspirin: by Application(USD Million)
  • Table 6. Aspirin Tablets Product , by Region USD Million (2017-2022)
  • Table 7. Aspirin Capsule Product , by Region USD Million (2017-2022)
  • Table 8. Aspirin Others , by Region USD Million (2017-2022)
  • Table 9. Aspirin: by End-User(USD Million)
  • Table 10. Aspirin Hospitals , by Region USD Million (2017-2022)
  • Table 11. Aspirin Ambulatory Surgical Center (ASC) , by Region USD Million (2017-2022)
  • Table 12. Aspirin Others , by Region USD Million (2017-2022)
  • Table 13. South America Aspirin, by Country USD Million (2017-2022)
  • Table 14. South America Aspirin, by Type USD Million (2017-2022)
  • Table 15. South America Aspirin, by Application USD Million (2017-2022)
  • Table 16. South America Aspirin, by End-User USD Million (2017-2022)
  • Table 17. Brazil Aspirin, by Type USD Million (2017-2022)
  • Table 18. Brazil Aspirin, by Application USD Million (2017-2022)
  • Table 19. Brazil Aspirin, by End-User USD Million (2017-2022)
  • Table 20. Argentina Aspirin, by Type USD Million (2017-2022)
  • Table 21. Argentina Aspirin, by Application USD Million (2017-2022)
  • Table 22. Argentina Aspirin, by End-User USD Million (2017-2022)
  • Table 23. Rest of South America Aspirin, by Type USD Million (2017-2022)
  • Table 24. Rest of South America Aspirin, by Application USD Million (2017-2022)
  • Table 25. Rest of South America Aspirin, by End-User USD Million (2017-2022)
  • Table 26. Asia Pacific Aspirin, by Country USD Million (2017-2022)
  • Table 27. Asia Pacific Aspirin, by Type USD Million (2017-2022)
  • Table 28. Asia Pacific Aspirin, by Application USD Million (2017-2022)
  • Table 29. Asia Pacific Aspirin, by End-User USD Million (2017-2022)
  • Table 30. China Aspirin, by Type USD Million (2017-2022)
  • Table 31. China Aspirin, by Application USD Million (2017-2022)
  • Table 32. China Aspirin, by End-User USD Million (2017-2022)
  • Table 33. Japan Aspirin, by Type USD Million (2017-2022)
  • Table 34. Japan Aspirin, by Application USD Million (2017-2022)
  • Table 35. Japan Aspirin, by End-User USD Million (2017-2022)
  • Table 36. India Aspirin, by Type USD Million (2017-2022)
  • Table 37. India Aspirin, by Application USD Million (2017-2022)
  • Table 38. India Aspirin, by End-User USD Million (2017-2022)
  • Table 39. South Korea Aspirin, by Type USD Million (2017-2022)
  • Table 40. South Korea Aspirin, by Application USD Million (2017-2022)
  • Table 41. South Korea Aspirin, by End-User USD Million (2017-2022)
  • Table 42. Taiwan Aspirin, by Type USD Million (2017-2022)
  • Table 43. Taiwan Aspirin, by Application USD Million (2017-2022)
  • Table 44. Taiwan Aspirin, by End-User USD Million (2017-2022)
  • Table 45. Australia Aspirin, by Type USD Million (2017-2022)
  • Table 46. Australia Aspirin, by Application USD Million (2017-2022)
  • Table 47. Australia Aspirin, by End-User USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Aspirin, by Type USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Aspirin, by Application USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Aspirin, by End-User USD Million (2017-2022)
  • Table 51. Europe Aspirin, by Country USD Million (2017-2022)
  • Table 52. Europe Aspirin, by Type USD Million (2017-2022)
  • Table 53. Europe Aspirin, by Application USD Million (2017-2022)
  • Table 54. Europe Aspirin, by End-User USD Million (2017-2022)
  • Table 55. Germany Aspirin, by Type USD Million (2017-2022)
  • Table 56. Germany Aspirin, by Application USD Million (2017-2022)
  • Table 57. Germany Aspirin, by End-User USD Million (2017-2022)
  • Table 58. France Aspirin, by Type USD Million (2017-2022)
  • Table 59. France Aspirin, by Application USD Million (2017-2022)
  • Table 60. France Aspirin, by End-User USD Million (2017-2022)
  • Table 61. Italy Aspirin, by Type USD Million (2017-2022)
  • Table 62. Italy Aspirin, by Application USD Million (2017-2022)
  • Table 63. Italy Aspirin, by End-User USD Million (2017-2022)
  • Table 64. United Kingdom Aspirin, by Type USD Million (2017-2022)
  • Table 65. United Kingdom Aspirin, by Application USD Million (2017-2022)
  • Table 66. United Kingdom Aspirin, by End-User USD Million (2017-2022)
  • Table 67. Netherlands Aspirin, by Type USD Million (2017-2022)
  • Table 68. Netherlands Aspirin, by Application USD Million (2017-2022)
  • Table 69. Netherlands Aspirin, by End-User USD Million (2017-2022)
  • Table 70. Rest of Europe Aspirin, by Type USD Million (2017-2022)
  • Table 71. Rest of Europe Aspirin, by Application USD Million (2017-2022)
  • Table 72. Rest of Europe Aspirin, by End-User USD Million (2017-2022)
  • Table 73. MEA Aspirin, by Country USD Million (2017-2022)
  • Table 74. MEA Aspirin, by Type USD Million (2017-2022)
  • Table 75. MEA Aspirin, by Application USD Million (2017-2022)
  • Table 76. MEA Aspirin, by End-User USD Million (2017-2022)
  • Table 77. Middle East Aspirin, by Type USD Million (2017-2022)
  • Table 78. Middle East Aspirin, by Application USD Million (2017-2022)
  • Table 79. Middle East Aspirin, by End-User USD Million (2017-2022)
  • Table 80. Africa Aspirin, by Type USD Million (2017-2022)
  • Table 81. Africa Aspirin, by Application USD Million (2017-2022)
  • Table 82. Africa Aspirin, by End-User USD Million (2017-2022)
  • Table 83. North America Aspirin, by Country USD Million (2017-2022)
  • Table 84. North America Aspirin, by Type USD Million (2017-2022)
  • Table 85. North America Aspirin, by Application USD Million (2017-2022)
  • Table 86. North America Aspirin, by End-User USD Million (2017-2022)
  • Table 87. United States Aspirin, by Type USD Million (2017-2022)
  • Table 88. United States Aspirin, by Application USD Million (2017-2022)
  • Table 89. United States Aspirin, by End-User USD Million (2017-2022)
  • Table 90. Canada Aspirin, by Type USD Million (2017-2022)
  • Table 91. Canada Aspirin, by Application USD Million (2017-2022)
  • Table 92. Canada Aspirin, by End-User USD Million (2017-2022)
  • Table 93. Mexico Aspirin, by Type USD Million (2017-2022)
  • Table 94. Mexico Aspirin, by Application USD Million (2017-2022)
  • Table 95. Mexico Aspirin, by End-User USD Million (2017-2022)
  • Table 96. Aspirin: by Type(USD/Units)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Aspirin: by Type(USD Million)
  • Table 116. Aspirin 99.5% Purity , by Region USD Million (2023-2028)
  • Table 117. Aspirin 99% Purity , by Region USD Million (2023-2028)
  • Table 118. Aspirin Others , by Region USD Million (2023-2028)
  • Table 119. Aspirin: by Application(USD Million)
  • Table 120. Aspirin Tablets Product , by Region USD Million (2023-2028)
  • Table 121. Aspirin Capsule Product , by Region USD Million (2023-2028)
  • Table 122. Aspirin Others , by Region USD Million (2023-2028)
  • Table 123. Aspirin: by End-User(USD Million)
  • Table 124. Aspirin Hospitals , by Region USD Million (2023-2028)
  • Table 125. Aspirin Ambulatory Surgical Center (ASC) , by Region USD Million (2023-2028)
  • Table 126. Aspirin Others , by Region USD Million (2023-2028)
  • Table 127. South America Aspirin, by Country USD Million (2023-2028)
  • Table 128. South America Aspirin, by Type USD Million (2023-2028)
  • Table 129. South America Aspirin, by Application USD Million (2023-2028)
  • Table 130. South America Aspirin, by End-User USD Million (2023-2028)
  • Table 131. Brazil Aspirin, by Type USD Million (2023-2028)
  • Table 132. Brazil Aspirin, by Application USD Million (2023-2028)
  • Table 133. Brazil Aspirin, by End-User USD Million (2023-2028)
  • Table 134. Argentina Aspirin, by Type USD Million (2023-2028)
  • Table 135. Argentina Aspirin, by Application USD Million (2023-2028)
  • Table 136. Argentina Aspirin, by End-User USD Million (2023-2028)
  • Table 137. Rest of South America Aspirin, by Type USD Million (2023-2028)
  • Table 138. Rest of South America Aspirin, by Application USD Million (2023-2028)
  • Table 139. Rest of South America Aspirin, by End-User USD Million (2023-2028)
  • Table 140. Asia Pacific Aspirin, by Country USD Million (2023-2028)
  • Table 141. Asia Pacific Aspirin, by Type USD Million (2023-2028)
  • Table 142. Asia Pacific Aspirin, by Application USD Million (2023-2028)
  • Table 143. Asia Pacific Aspirin, by End-User USD Million (2023-2028)
  • Table 144. China Aspirin, by Type USD Million (2023-2028)
  • Table 145. China Aspirin, by Application USD Million (2023-2028)
  • Table 146. China Aspirin, by End-User USD Million (2023-2028)
  • Table 147. Japan Aspirin, by Type USD Million (2023-2028)
  • Table 148. Japan Aspirin, by Application USD Million (2023-2028)
  • Table 149. Japan Aspirin, by End-User USD Million (2023-2028)
  • Table 150. India Aspirin, by Type USD Million (2023-2028)
  • Table 151. India Aspirin, by Application USD Million (2023-2028)
  • Table 152. India Aspirin, by End-User USD Million (2023-2028)
  • Table 153. South Korea Aspirin, by Type USD Million (2023-2028)
  • Table 154. South Korea Aspirin, by Application USD Million (2023-2028)
  • Table 155. South Korea Aspirin, by End-User USD Million (2023-2028)
  • Table 156. Taiwan Aspirin, by Type USD Million (2023-2028)
  • Table 157. Taiwan Aspirin, by Application USD Million (2023-2028)
  • Table 158. Taiwan Aspirin, by End-User USD Million (2023-2028)
  • Table 159. Australia Aspirin, by Type USD Million (2023-2028)
  • Table 160. Australia Aspirin, by Application USD Million (2023-2028)
  • Table 161. Australia Aspirin, by End-User USD Million (2023-2028)
  • Table 162. Rest of Asia-Pacific Aspirin, by Type USD Million (2023-2028)
  • Table 163. Rest of Asia-Pacific Aspirin, by Application USD Million (2023-2028)
  • Table 164. Rest of Asia-Pacific Aspirin, by End-User USD Million (2023-2028)
  • Table 165. Europe Aspirin, by Country USD Million (2023-2028)
  • Table 166. Europe Aspirin, by Type USD Million (2023-2028)
  • Table 167. Europe Aspirin, by Application USD Million (2023-2028)
  • Table 168. Europe Aspirin, by End-User USD Million (2023-2028)
  • Table 169. Germany Aspirin, by Type USD Million (2023-2028)
  • Table 170. Germany Aspirin, by Application USD Million (2023-2028)
  • Table 171. Germany Aspirin, by End-User USD Million (2023-2028)
  • Table 172. France Aspirin, by Type USD Million (2023-2028)
  • Table 173. France Aspirin, by Application USD Million (2023-2028)
  • Table 174. France Aspirin, by End-User USD Million (2023-2028)
  • Table 175. Italy Aspirin, by Type USD Million (2023-2028)
  • Table 176. Italy Aspirin, by Application USD Million (2023-2028)
  • Table 177. Italy Aspirin, by End-User USD Million (2023-2028)
  • Table 178. United Kingdom Aspirin, by Type USD Million (2023-2028)
  • Table 179. United Kingdom Aspirin, by Application USD Million (2023-2028)
  • Table 180. United Kingdom Aspirin, by End-User USD Million (2023-2028)
  • Table 181. Netherlands Aspirin, by Type USD Million (2023-2028)
  • Table 182. Netherlands Aspirin, by Application USD Million (2023-2028)
  • Table 183. Netherlands Aspirin, by End-User USD Million (2023-2028)
  • Table 184. Rest of Europe Aspirin, by Type USD Million (2023-2028)
  • Table 185. Rest of Europe Aspirin, by Application USD Million (2023-2028)
  • Table 186. Rest of Europe Aspirin, by End-User USD Million (2023-2028)
  • Table 187. MEA Aspirin, by Country USD Million (2023-2028)
  • Table 188. MEA Aspirin, by Type USD Million (2023-2028)
  • Table 189. MEA Aspirin, by Application USD Million (2023-2028)
  • Table 190. MEA Aspirin, by End-User USD Million (2023-2028)
  • Table 191. Middle East Aspirin, by Type USD Million (2023-2028)
  • Table 192. Middle East Aspirin, by Application USD Million (2023-2028)
  • Table 193. Middle East Aspirin, by End-User USD Million (2023-2028)
  • Table 194. Africa Aspirin, by Type USD Million (2023-2028)
  • Table 195. Africa Aspirin, by Application USD Million (2023-2028)
  • Table 196. Africa Aspirin, by End-User USD Million (2023-2028)
  • Table 197. North America Aspirin, by Country USD Million (2023-2028)
  • Table 198. North America Aspirin, by Type USD Million (2023-2028)
  • Table 199. North America Aspirin, by Application USD Million (2023-2028)
  • Table 200. North America Aspirin, by End-User USD Million (2023-2028)
  • Table 201. United States Aspirin, by Type USD Million (2023-2028)
  • Table 202. United States Aspirin, by Application USD Million (2023-2028)
  • Table 203. United States Aspirin, by End-User USD Million (2023-2028)
  • Table 204. Canada Aspirin, by Type USD Million (2023-2028)
  • Table 205. Canada Aspirin, by Application USD Million (2023-2028)
  • Table 206. Canada Aspirin, by End-User USD Million (2023-2028)
  • Table 207. Mexico Aspirin, by Type USD Million (2023-2028)
  • Table 208. Mexico Aspirin, by Application USD Million (2023-2028)
  • Table 209. Mexico Aspirin, by End-User USD Million (2023-2028)
  • Table 210. Aspirin: by Type(USD/Units)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Aspirin: by Type USD Million (2017-2022)
  • Figure 5. Global Aspirin: by Application USD Million (2017-2022)
  • Figure 6. Global Aspirin: by End-User USD Million (2017-2022)
  • Figure 7. South America Aspirin Share (%), by Country
  • Figure 8. Asia Pacific Aspirin Share (%), by Country
  • Figure 9. Europe Aspirin Share (%), by Country
  • Figure 10. MEA Aspirin Share (%), by Country
  • Figure 11. North America Aspirin Share (%), by Country
  • Figure 12. Global Aspirin: by Type USD/Units (2017-2022)
  • Figure 13. Global Aspirin share by Players 2022 (%)
  • Figure 14. Global Aspirin share by Players (Top 3) 2022(%)
  • Figure 15. Global Aspirin share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 18. Bayer (Germany) Revenue: by Geography 2022
  • Figure 19. Novacap (Canada) Revenue, Net Income and Gross profit
  • Figure 20. Novacap (Canada) Revenue: by Geography 2022
  • Figure 21. Shiono Chemical Co. (Japan) Revenue, Net Income and Gross profit
  • Figure 22. Shiono Chemical Co. (Japan) Revenue: by Geography 2022
  • Figure 23. Chemische Fabrik Weyl Gmbh (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Chemische Fabrik Weyl Gmbh (Germany) Revenue: by Geography 2022
  • Figure 25. Eli Lilly And Co (United States) Revenue, Net Income and Gross profit
  • Figure 26. Eli Lilly And Co (United States) Revenue: by Geography 2022
  • Figure 27. Industria Quimica Andina Y Cia Sa (Colombia) Revenue, Net Income and Gross profit
  • Figure 28. Industria Quimica Andina Y Cia Sa (Colombia) Revenue: by Geography 2022
  • Figure 29. Jqc Huayin Pharmaceutical Co Ltd (China) Revenue, Net Income and Gross profit
  • Figure 30. Jqc Huayin Pharmaceutical Co Ltd (China) Revenue: by Geography 2022
  • Figure 31. Lohmann Lts (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Lohmann Lts (Germany) Revenue: by Geography 2022
  • Figure 33. Novacyl Sas (France) Revenue, Net Income and Gross profit
  • Figure 34. Novacyl Sas (France) Revenue: by Geography 2022
  • Figure 35. Upjohn Co (United States) Revenue, Net Income and Gross profit
  • Figure 36. Upjohn Co (United States) Revenue: by Geography 2022
  • Figure 37. Shandong Xinhua Pharmaceutical Co Ltd (China) Revenue, Net Income and Gross profit
  • Figure 38. Shandong Xinhua Pharmaceutical Co Ltd (China) Revenue: by Geography 2022
  • Figure 39. The Andhra Sugars Ltd (India) Revenue, Net Income and Gross profit
  • Figure 40. The Andhra Sugars Ltd (India) Revenue: by Geography 2022
  • Figure 41. Dow Chemical Co (United States) Revenue, Net Income and Gross profit
  • Figure 42. Dow Chemical Co (United States) Revenue: by Geography 2022
  • Figure 43. Alfred Benzon As (Denmark) Revenue, Net Income and Gross profit
  • Figure 44. Alfred Benzon As (Denmark) Revenue: by Geography 2022
  • Figure 45. Eurand America Inc (United States) Revenue, Net Income and Gross profit
  • Figure 46. Eurand America Inc (United States) Revenue: by Geography 2022
  • Figure 47. Industries Monfel S.A. De C.V. (Mexico) Revenue, Net Income and Gross profit
  • Figure 48. Industries Monfel S.A. De C.V. (Mexico) Revenue: by Geography 2022
  • Figure 49. Nanjing Pharmaceutical Factory (China) Revenue, Net Income and Gross profit
  • Figure 50. Nanjing Pharmaceutical Factory (China) Revenue: by Geography 2022
  • Figure 51. Jilin Pharmaceutical (United States) Revenue, Net Income and Gross profit
  • Figure 52. Jilin Pharmaceutical (United States) Revenue: by Geography 2022
  • Figure 53. Global Aspirin: by Type USD Million (2023-2028)
  • Figure 54. Global Aspirin: by Application USD Million (2023-2028)
  • Figure 55. Global Aspirin: by End-User USD Million (2023-2028)
  • Figure 56. South America Aspirin Share (%), by Country
  • Figure 57. Asia Pacific Aspirin Share (%), by Country
  • Figure 58. Europe Aspirin Share (%), by Country
  • Figure 59. MEA Aspirin Share (%), by Country
  • Figure 60. North America Aspirin Share (%), by Country
  • Figure 61. Global Aspirin: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Bayer (Germany)
  • Novacap (Canada)
  • Shiono Chemical Co. (Japan)
  • Chemische Fabrik Weyl Gmbh (Germany)
  • Eli Lilly And Co (United States)
  • Industria Quimica Andina Y Cia Sa (Colombia)
  • Jqc Huayin Pharmaceutical Co Ltd (China)
  • Lohmann Lts (Germany)
  • Novacyl Sas (France)
  • Upjohn Co (United States)
  • Shandong Xinhua Pharmaceutical Co Ltd (China)
  • The Andhra Sugars Ltd (India)
  • Dow Chemical Co (United States)
  • Alfred Benzon As (Denmark)
  • Eurand America Inc (United States)
  • Industries Monfel S.A. De C.V. (Mexico)
  • Nanjing Pharmaceutical Factory (China)
  • Jilin Pharmaceutical (United States)
Additional players considered in the study are as follows:
Zhongnan Pharmaceutical (China) , Jiuming Pharmaceutical (China) , Hubei Ocean Biotech Co (China)
Select User Access Type

Key Highlights of Report


Apr 2023 219 Pages 85 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Aspirin Market Quantitative research analysis
Global and Regional Aspirin Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Aspirin Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Aspirin market is dominated by Chinese, United States Players and may generate healthy valuation by 2028.
  • Increasing headache, stress-related work and rise in demand for advanced medical device
  • The surging number of cigarette consumers
dominated the Aspirin market. This is attributable to growing trend of "Surging use of electronic aspirin"

Know More About Global and Regional Aspirin Market Report?

Have a Query? Click Here

Other Related Reports

First Aid Comprehensive Study by Type (Adhesive Bandages, Gauses, Disinfectants, Others), Application (Clinic, Hospital, Home Use) Players and Region - Global Market Outlook to 2030
$ 3500
Glucosamine and Chondroitin Sulfate Comprehensive Study by Application (Pharmaceutical, Dietary Supplements (Animal Feed, Nutraceuticals), Cosmetics, Others), Source (Bovine, Swine, Poultry, Shark, S...
$ 3500
Rasagiline Tablet Comprehensive Study by Type (0.5 mg Tablet, 1 mg Tablet, Others), Application (Clinics and Hospital, Households, Caring Center, Others), Distribution Channel (Online Channels, Offli...
$ 3500
Nasal Polyposis Drug Comprehensive Study by Route of Administration (Oral, Nasal, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Drug Class (Cortic...
$ 3650
Lymphoma Drugs Comprehensive Study by Type (Hodgkin Lymphoma (HL) Drugs, Non-Hodgkin Lymphoma (NHL) Drugs), Lymphoma Treatment Drug (Adcetris, Opdivo, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid,...
$ 3450
Primary Antibodies Comprehensive Study by Type (Monoclonal Antibodies, Polyclonal Antibodies), Application (Proteomics, Drug Development, Genomics), End-users (Pharmaceutical and Biotechnological Com...
$ 3750